Goodwill

Beginning January 2018, the Company comprised of two reportable segments: Rare Disease and Neuroscience. For more information regarding the Company's segments refer to Note 21, Segment Reporting, to these Unaudited Consolidated Financial Statements.

The following table provides a roll-forward of the Goodwill balance by segment, for the three months ended March 31, 2018:



	2018
(In millions)	Rare Disease			Neuroscience		Total
As of January 1,	$	16,281.8		$	3,549.9	$	19,831.7
Changes	(25.8		)	—		(25.8		)
Foreign currency translation	150.0			32.7		182.7
March 31,	$	16,406.0		$	3,582.6	$	19,988.6

The following table provides a roll-forward of the Goodwill balance for the three months ended March 31, 2017:



	2017
(In millions)	Rare Disease		Neuroscience		Total
As of January 1,	$	14,493.5	$	3,394.7	$	17,888.2
Acquisitions	1,213.8		—		1,213.8
Foreign currency translation	38.7		8.4		47.1
As of March 31,	$	15,746.0	$	3,403.1	$	19,149.1

The increase in Goodwill during the three months ended March 31, 2017 related to measurement period adjustments of the acquisition of Baxalta.